Cirius Therapeutics ciriustx.com


Cirius Therapeutics, formerly Octeta Therapeutics, a clinical-stage pharmaceutical company, is developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novel insulin sensitizing mechanism of action, MSDC-0602K has potential to resolve the underlying pathophysiology of NASH.

Cirius Therapeutics, formerly Octeta Therapeutics, a clinical-stage pharmaceutical company, is developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluat...Show all

Company (Alive / Active)

Phone: 269-343-6732

Fax:

161 East Michigan Avenue
Suite 400
Kalamazoo, 49007
Michigan, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Cirius Therapeutics $56.4M Apr 10, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Cirius Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 3 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)